Holen Sie sich die Stockscreener-App
0.21
0.96%
0.002
Handel nachbörslich:
.21
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
Outlook Therapeutics closes $5 million stock offering By Investing.com - Investing.com Australia
Published on: 2026-03-26 16:05:05 - baoquankhu1.vn
Outlook Therapeutics Announces $500,000 Public Offering of Common Stock and Warrants - Minichart
Outlook Therapeutics Completes Dilutive Equity Offering With Warrants - TipRanks
Outlook Therapeutics closes 5.0 million dollar public offering to boost capital - Traders Union
Outlook Therapeutics commences $5.0M best-efforts offering of common stock with 1-for-1 warrants - TradingView
[8-K] Outlook Therapeutics, Inc. Reports Mat... - Stock Titan
Outlook Therapeutics closes $5 million stock offering - Investing.com
Outlook Therapeutics sells 20M shares, closes $5M financing - Stock Titan
Outlook Therapeutics (OTLK) launches 20M-share offering with detachable warrants - Stock Titan
Outlook Therapeutics prices $5M stock offering at $0.25 per share - Investing.com Australia
Outlook Therapeutics stock prices $5M offering at $0.25 per share amid Nasdaq plunge and biotech fun - AD HOC NEWS
Outlook Therapeutics Shares Drop After $5 Million Public Offering Priced - marketscreener.com
Why is OTLK stock falling today? - MSN
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
20M new shares at 25 cents: Outlook prices $5M fundraise - Stock Titan
Why Is OTLK Stock Falling Today? - Stocktwits
Biggest stock movers Tuesday: CLB, OTLK, and more (NASDAQ:NTGR) - Seeking Alpha
Outlook Therapeutics launches public stock offering By Investing.com - Investing.com Canada
Outlook Therapeutics announces proposed public offering sending shares into focus - Traders Union
Outlook Therapeutics (OTLK) Launches Public Offering, Shares Sli - GuruFocus
Outlook Therapeutics Announces Proposed Public Offering - The Manila Times
Outlook Therapeutics launches public stock offering - Investing.com
Outlook Therapeutics announces proposed public offering - marketscreener.com
Eye-disease drug developer seeks cash in stock-and-warrant sale - Stock Titan
Outlook Therapeutics (OTLK) offers common stock, pre-funded warrants and common warrants - Stock Titan
OTLK Stock Price, Quote & Chart | OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) - ChartMill
Whale Trades: Is Outlook Therapeutics Inc a top pick in the sector2026 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
Outlook Therapeutics secures $18.4M note, extends debt maturity By Investing.com - Investing.com India
Outlook Therapeutics Faces Substantial Doubt as a Going Concern Amid Funding Shortfall and Ongoing FDA Setbacks for ONS-5010/LYTENAVA 1234567 - Minichart
Outlook Therapeutics, Inc. announced that it has received $18.36 million in funding from Atlas Sciences, LLC - marketscreener.com
Outlook Therapeutics (OTLK) Restructures Debt with New Financing Moves - GuruFocus
Outlook Therapeutics Refinances Debt, Extends Note Maturities - TipRanks
Outlook Therapeutics Secures $17 Million Atlas Note to Refinance Avondale Debt - TradingView
Outlook Therapeutics (OTLK) refinances debt with $18.36M note amid going concern risks - Stock Titan
Outlook Therapeutics announces new $18.4 million non-convertible note financing and amendment to existing convertible note - marketscreener.com
Outlook Therapeutics secures $18.4M note, extends debt maturity - Investing.com
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note - Bitget
Outlook Therapeutics Amends Current Convertible Note With Avondale Capital To Extend Maturity Through Dec. 31; Signs $18.4M New NoteOutlook Therapeutics (NASDAQ:OTLK) - Benzinga
Outlook Therapeutics Announces New $18.4 Million - GlobeNewswire
Options Flow: Can Outlook Therapeutics Inc reach all time highs this year2026 Sentiment & Capital Efficient Trading Techniques - baoquankhu1.vn
Outlook Therapeutics Announces Board Resignation and Size Reduction - The Globe and Mail
Outlook Therapeutics Shareholders Back Board, Pay, and Auditor - The Globe and Mail
Outlook Therapeutics' Dr. Julia Haller resigns from board; size reduced to nine - TradingView
Outlook Therapeutics, Inc. Announces Resignation of Dr. Julia Haller from the Board and Member of the Nominating and Corporate Governance Committee, Effective March 11, 2026 - marketscreener.com
Outlook Therapeutics (NASDAQ: OTLK) trims board to nine directors - Stock Titan
Ascendiant Capital Lowers Price Target for Outlook Therapeutics (OTLK) | OTLK Stock News - GuruFocus
Shareholders at Outlook Therapeutics (NASDAQ: OTLK) approve board slate - Stock Titan
Outlook Therapeutics discusses FDA meeting on bevacizumab drug - Investing.com Nigeria
Published on: 2026-03-10 21:03:39 - baoquankhu1.vn
Key facts: Outlook Therapeutics Engages FDA on ONS-5010 Approval Pathways - TradingView
Outlook Therapeutics discusses FDA meeting on bevacizumab drug By Investing.com - Investing.com Australia
OUTLOOK THERAPEUTICS INC share price - Mint
Outlook Therapeutics Updates FDA Path For ONS-5010 Following Type A Meeting - Nasdaq
FDA meeting prompts new ONS-5010 update, Outlook Therapeutics outlines - Traders Union
Outlook Therapeutics (OTLK) Advances Towards FDA Approval for ONS-5010 - GuruFocus
Outlook Therapeutics advances FDA dialogue on ONS-5010 approval - TipRanks
0.04%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):